Through its rich portfolio and notable partnerships, Precision BioPharma, Inc. is developing the next generation of antiviral treatments. The company uses adaptive translational research and artificial intelligence to rapidly identify and characterize new drugs and targets. Precision BioPharma’s team is comprised of seasoned experts in artificial intelligence, genomics, drug discovery and development, clinical trials and regulatory affairs.
Kumar is the inventor of Precision BioPharma’s leading antiviral drug candidate, PB-004. The company has submitted pre-IND application to the U.S. Food & Drug Administration for PB-004 and is planning clinical trials by the end of 2021.